New Migraine Drug Shows Promise in Clinical Trial

A biotechnology company has developed elismetrep, a novel drug that works differently from existing migraine treatments and could help the 70% of patients who don't find relief with current options.

The drug targets a previously unexplored pathway in pain neurons, offering new hope for millions of migraine sufferers.